多西他赛周疗法联合同步放疗治疗食管癌的临床观察

Clinical observation of docetaxel weekly therapy combined with concurrent radiotherapy in the treatment of esophagus cancer

目的观察多西他赛周疗法联合同步放疗治疗食管癌的临床疗效。方法 88例食管癌患者,根据治疗方法的不同分为观察组和对照组,各44例。对照组采用单纯放疗进行治疗;观察组在单纯放疗的基础上采用多西他赛周疗法进行化疗。对比两组患者治疗前后的白细胞介素-6(IL-6)、血清C反应蛋白(CRP)、白细胞介素-8(IL-8)、可溶性MHC-1分子链相关基因A(s MICA),并比较两组患者治疗后的临床效果。结果治疗后观察组患者的血清CRP、IL-6、IL-8、s MICA水平显著优于对照组,差异具有统计学意义(P<0.05)。观察组患者的治疗效果优于对照组,差异具有统计学意义(P<0.05)。两组患者的不良反应率差异无统计学意义(P>0.05)。患者的不良反应未受到化疗和放疗的影响。结论多西他赛周疗法联合同步放疗治疗食管癌临床效果显著,可以在临床上进一步推广和使用。

Objective To observe clinical effect of docetaxel weekly therapy combined with concurrent radiotherapy in the treatment of esophagus cancer. Methods A total of 88 esophagus cancer patients were divided by different treatment methods into observation group and control group, with 44 cases in each group. The control group received single radiotherapy therapy, and the observation group received additional docetaxel weekly therapy for chemotherapy. Comparisons were made on interleukin-6 （IL-6）, serum C-reactive protein （CRP）, interleukin-8 （IL-8）, soluble MHC-1 chain-related gene A （sMICA） before and after treatment in the two groups, along with their clinical effects. Results After treatment, the observation group had much better levels of serum CRP, IL-6, IL-8, and sMICA than the control group, and their differences had statistical significance （/）〈0.05）. Curative effect was obviously higher in the observation group than in the control group, and the difference had statistical significance （P〈0.05）. There were no statistically significant difference of adverse reactions rates between the two groups （P〉0.05）. Adverse reactions in patients were not under the influence by chemotherapy and radiotherapy. Conclusion Docetaxel weekly therapy combined with concurrent radiotherapy provide significant effect in treating esophagus cancer, and this method can be further promoted and applied in clinic.